Dry Eye Clinical Trial
Official title:
Prospective, Randomized, Masked, Controlled Trial To Evaluate The Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)
Verified date | September 2022 |
Source | Sight Sciences, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To demonstrate the safety and effectiveness of TearCare® procedures compared to Restasis® to treat the signs and symptoms of dry eye disease in adult patients.
Status | Active, not recruiting |
Enrollment | 350 |
Est. completion date | May 22, 2024 |
Est. primary completion date | March 22, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 22 Years and older |
Eligibility | Inclusion Criteria: - At least 22 years of age - Reports dry eye symptoms within the past 3 to 6 months - Reports having to use artificial tears or lubricants regularly over the past month to relieve dry eye symptoms. - Schirmer tear test (with anesthesia) =1 to =10 mm in 5 minutes - OSDI Score of 23-79 - TBUT of =1 to =7 seconds in both eyes - Meibomian gland obstruction in both eyes based on a total Meibomian Gland Secretion Score =12 in each eye. - At least 15 glands in each lower eyelid should be expressible, with a sterile cotton swab, at the slit lamp. - Best corrected visual acuity of 20/100 or better in both eyes. - Willing and able to comply with the study procedures and follow-up - Willing and able to provide informed consent - English-speaking Exclusion Criteria: - Use of any of the following medications: 1. Cyclosporine (Restasis, Cequa etc.) or Xiidra within 60 days prior to enrollment; 2. Antihistamines (oral or topical) within 10 days prior to enrollment; 3. Systemic medication(s) (other than antihistamines) that is known to cause ocular dryness (e.g. diuretics, anti-hypertensives, anti-depressants, hormone therapy) and whose dose of this medication(s) has not been stable within 30 days prior to enrollment. There must be no anticipated adjustments to the dose of these medications for the duration of the trial; 4. Accutane (at any time); 5. Oral tetracyclines or azithromycin within 30 days prior to enrollment; or 6. Topical ophthalmic antibiotics, anti-glaucoma medications, steroids, non-steroidal anti- inflammatory medications within 30 days prior to enrollment. - Any of the following dry eye treatments: 1. Office-based dry eye treatment (e.g. IPL, TearCare, thermal pulsation [Lipiflow], iLux etc.) within 12 months prior to enrollment either as part of routine care or clinical investigation; 2. Meibomian gland expression within 6 months prior to enrollment; 3. Blephex or debridement within 3 months prior to enrollment is an exclusion; 4. Punctal occlusion or punctal plugs. Investigators can choose to remove the punctal plugs 15 days prior to enrollment; 5. Use of TrueTear device within the past 2 weeks. (Subjects must refrain from using the TrueTear device for the duration of the study.); or 6. Any history of meibomian gland probing - History of eyelid, conjunctiva or corneal surgery (including refractive surgery) within the past year. In addition, subjects with any history of the following are excluded: chalazion surgery, surgery on the tarsal conjunctiva, radial keratotomy (RK), complicated blepharoplasty, lid reconstruction, or significant complications post-refractive surgery. - Contact lens use within the past 2 weeks. - History of Ocular Herpes Simplex or Ocular Herpes Zoster - Any active, clinically significant ocular or peri-ocular infection or inflammation - Recurrent clinically significant eye inflammation, other than dry eye, within 3 months prior to enrollment - Clinically significant anterior blepharitis. In addition, collarettes or flakes of more than one quarter of the eyelid are excluded. - Clinically significant eyelid abnormalities in either eye (e.g. entropion/ectropion, blepharospasm, aponeurotic ptosis, lagophthalmos, distichiasis, trichiasis). - Clinically significant dermatologic or cutaneous disease of the eyelid or periocular area. |
Country | Name | City | State |
---|---|---|---|
United States | Vantage Eye Care | Bala-Cynwyd | Pennsylvania |
United States | Vision Institute | Colorado Springs | Colorado |
United States | Cincinnati Eye Institute | Edgewood | Kentucky |
United States | Scripps Health | La Jolla | California |
United States | Harvard Eye Associates | Laguna Hills | California |
United States | Jackson Eye | Lake Villa | Illinois |
United States | Kentucky Eye Institute | Lexington | Kentucky |
United States | Loh Ophthalmology Associates | Miami | Florida |
United States | Eye Research Foundation | Newport Beach | California |
United States | University of Pittsburg-Ophthalmology Dept | Pittsburgh | Pennsylvania |
United States | Parkhurst NuVision | San Antonio | Texas |
United States | Doctor My Eyes | Scottsdale | Arizona |
United States | Vita Eye Clinic | Shelby | North Carolina |
United States | Vance Thompson Vision | Sioux Falls | South Dakota |
Lead Sponsor | Collaborator |
---|---|
Sight Sciences, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Tear Break-Up Time | Mean Change from baseline in Tear Break-Up Time (TBUT) | 6 months | |
Primary | OSDI Score | Mean Change from baseline in OSDI score | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05027087 -
The Effect of a Novel Blueberry Supplement on Dry Eye Disease
|
Phase 3 | |
Completed |
NCT05102409 -
An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease
|
Phase 2 | |
Completed |
NCT06159569 -
Performance and Tolerability of the Medical Device LACRIACT
|
N/A | |
Completed |
NCT04081610 -
Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution
|
Phase 1 | |
Completed |
NCT05062564 -
Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye
|
N/A | |
Completed |
NCT05825599 -
PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms
|
N/A | |
Completed |
NCT03418727 -
Dry Eye Disease Study With Brimonidine
|
Phase 2 | |
Active, not recruiting |
NCT04425551 -
Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction
|
N/A | |
Recruiting |
NCT04527887 -
Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)
|
Phase 4 | |
Not yet recruiting |
NCT06379685 -
Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.
|
Phase 1 | |
Active, not recruiting |
NCT05618730 -
Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B
|
Phase 1 | |
Completed |
NCT04553432 -
Dry Eye OmniLenz Application of Omnigen Research Study
|
Phase 4 | |
Recruiting |
NCT04109170 -
Dry Eye Evaluation System Based on Bioinformatics
|
||
Completed |
NCT04105842 -
Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type
|
N/A | |
Completed |
NCT05505292 -
Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
|
Phase 4 | |
Completed |
NCT04668131 -
Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease
|
N/A | |
Completed |
NCT06176651 -
Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers
|
Phase 4 | |
Completed |
NCT02235259 -
Efficacy and Safety of XG-104 for the Treatment of Dry Eye
|
Phase 2 | |
Not yet recruiting |
NCT02218827 -
Topical Steroid Treatment For Dry Eye
|
N/A | |
Completed |
NCT01959854 -
Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye
|
N/A |